Infliximab
CAS 170277-31-3Biologic
Overview
Infliximab is a chimeric monoclonal antibody that inhibits tumor necrosis factor-alpha (TNFα), a substance in the body that causes inflammation. It is used in the treatment of autoimmune diseases such as Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriasis, and rheumatoid arthritis.
Therapeutic areas
ImmunologyGastroenterologyRheumatology
Verified Supplier Partner
Do you supply Infliximab? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.